206 results on '"Czuczman, M."'
Search Results
2. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
3. Erector spinae plane block vs. peri‐articular injection for pain control after arthroscopic shoulder surgery: a randomised controlled trial
4. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
5. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma
6. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease
7. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients
8. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients
9. Erector spinae plane block vs. peri-articular injection for pain control after arthroscopic shoulder surgery: a randomised controlled trial.
10. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
11. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
12. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
13. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
14. 21. New Immunological Principles: 115 RESULTS FROM A PHASE I/II STUDY OF GALIXIMAB (ANTICD80) IN COMBINATION WITH RITUXIMAB (ANTI-CD20) FOR RELAPSED OR REFRACTORY, FOLLICULAR NHL
15. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma
16. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis
17. Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma
18. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
19. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS
20. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)
21. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA
22. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)
23. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO
24. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
25. Ofatumumab Combined with CHOP in Previously Untreated Patients with Follicular Lymhoma (FL)
26. Ofatumumab Combined With CHOP in Previously Untreated Patients With Follicular Lymphoma
27. Non-Hodgkin's lymphomas
28. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
29. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.
30. Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice
31. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
32. 611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies
33. Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
34. Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD.
35. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
36. Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003).
37. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).
38. Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL).
39. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).
40. 18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients.
41. Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma
42. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL)
43. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
44. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003)
45. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
46. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003)
47. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies
48. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma
49. Safety of lenalidomide monotherapy in patients with relapsed or refractory aggressive non-Hodgkin’s lymphom
50. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.